Clinical Trial Disruption Due to COVID-19: Interpreting & Communicating Data With Regulators

Regulatory

Mary Rofael, President of ProEd Regulatory, hosts a panel of experts to discuss how to interpret data from clinical trials disrupted because of the COVID-19 pandemic and how to best communicate these data with regulators.

Presenters/Moderators

Mary Rofael, MD, RAC

President, ProEd Regulatory

Thomas R. Fleming, PhD

Professor, Biostatistics and Statistics, University of Washington

Robert Makuch, PhD

Professor of Biostatistics and Director of the Regulatory Affairs Track, Yale University Schools of Medicine and of Public Health

Kannan Natarajan, PhD

Head of Global Biometrics and Data Management, Pfizer, Inc.

Joanne Palmisano, MD, FACP, FRAPS

Vice President, Head Global Regulatory Strategy, Vertex Pharmaceuticals, Inc

William White, MD

Medical and Scientific Consultant, Professor of Medicine, Calhoun Cardiology Center, University of Connecticut School of Medicine; past president, American Society of Hypertension

Other Webinars

Artificial Intelligence: Reality or Hyperbole?

Publications

FDA Advisory Committees: Effective Preparation in the Face of COVID-19 Uncertainty

Regulatory

More Information

The Collective Intelligence Webinars leverage the global expertise of the Healthcare Consultancy Group (HCG) to provide leading professionals across pharma and biotech with thought-leadership examples of future thinking, collaboration, and communication excellence.

HCG is a global leader in medical communications, comprising 7 interconnected agencies with distinct personalities and complementary skills.

The depth of our expertise allows us to configure custom solutions to meet your scientific, regulatory, and digital needs. Discrete offices and robust processes ensure the confidentiality of your data and programs.